Rosuvastatin

Latest stories

14d
Newsmax
Prescribing Brand Name Drugs Over Generics Costs Billionsexample, instead of prescribing AstraZeneca's Crestor, a statin drug for loweri
Prescribing Brand Name Drugs Over Generics Costs Billions
Newsmax / Posted 14 days ago
example, instead of prescribing AstraZeneca's Crestor, a statin drug for lowering high cholesterol, doctors might prescribe rosuvastatin, which is the less expensive generic form of Crestor. Another, less widely accepted approach is known as... Read more
2 related stories
14d
FOX News
Inefficient prescribing costs billions of healthcare dollarsexample, instead of prescribing AstraZeneca's Crestor, a statin drug for loweri
Inefficient prescribing costs billions of healthcare dollars
FOX News / Posted 14 days ago
example, instead of prescribing AstraZeneca's Crestor, a statin drug for lowering high cholesterol, doctors might prescribe rosuvastatin, which is the less expensive generic form of Crestor. Another, less widely accepted approach is known as... Read more
2 related stories
14d
Channel NewsAsia
Inefficient prescribing costs billions of healthcare dollarsexample, instead of prescribing AstraZeneca's Crestor, a statin drug for loweri
Inefficient prescribing costs billions of healthcare dollars
Channel NewsAsia / Posted 14 days ago
example, instead of prescribing AstraZeneca's Crestor, a statin drug for lowering high cholesterol, doctors might prescribe rosuvastatin, which is the less expensive generic form of Crestor. Another, less widely accepted approach is known as... Read more
2 related stories
19d
News-Medical-Net
Study shows short-term statin treatment does not benefit heart surgery patientsUniversity of Oxford, involved randomly giving 1,922 people scheduled for heart
Study shows short-term statin treatment does not benefit heart surgery patients
News-Medical-Net / Posted 19 days ago
University of Oxford, involved randomly giving 1,922 people scheduled for heart surgery either a daily dose of a statin (rosuvastatin 20 mg daily) or a matching placebo tablet. These people had a normal heart rhythm, so did not have AF before... Read more
25d
TheStreet.com
AstraZeneca First Quarter Fails to Ease Growth Worriespledged to maintain a high level of investment for the foreseeable future, as p
AstraZeneca First Quarter Fails to Ease Growth Worries
TheStreet.com / Posted 25 days ago
pledged to maintain a high level of investment for the foreseeable future, as part of an effort to offset the effects of a Rosuvastatin/Crestor franchise that is now perched on a cliff edge. Crestor is a blockbuster statin drug that is designed to... Read more
27d
New Kerala
Biocon net up 79 percent in fourth quarter - newkerala.com #55364insulin Glrgine became the first biosimilar from India and second to be approve
Biocon net up 79 percent in fourth quarter - newkerala.com #55364
New Kerala / Posted 27 days ago
insulin Glrgine became the first biosimilar from India and second to be approved in Japan. "EU approval for generic Rosuvastatin calcium tablets will enable us to take its first generic formulation to developed markets," the statement... Read more
65 related stories
27d
Business Standard India
Biocon expects more filings this year for biosimilars, drugsBiocon's biosimilar insulin Glargine got approval in Japan and also got approva
Biocon expects more filings this year for biosimilars, drugs
Business Standard India / Posted 27 days ago
Biocon's biosimilar insulin Glargine got approval in Japan and also got approval in the European Union for Biocon's generic Rosuvastatin Calcium tablets, its first generic formulation in the developed markets. It expects filings in FY17 after the... Read more
27d
The Financial Express
Exceptional income drives Biocon Q4 net up 79 % at Rs 361 croreof its biosimilars in the key regulated markets, Biocon said. Another importan
Exceptional income drives Biocon Q4 net up 79 % at Rs 361 crore
The Financial Express / Posted 27 days ago
of its biosimilars in the key regulated markets, Biocon said. Another important development was European approval for Rosuvastatin Calcium tablets which marks the entry of the company’s generic formulations foray in developed markets, it... Read more
65 related stories
27d
Business Standard India
Biocon's Q4 net profit jumps 250% to Rs 361 crore on exceptional incomeBiocon's biosimilar insulin Glargine got approval in Japan and also received no
Biocon's Q4 net profit jumps 250% to Rs 361 crore on exceptional income
Business Standard India / Posted 27 days ago
Biocon's biosimilar insulin Glargine got approval in Japan and also received nod in the European Union for Biocon's generic Rosuvastatin Calcium tablets, its first generic formulation in the developed markets. It expects filings in fiscal 2016-17... Read more

People in this news